A randomized Phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer

Clinical Cancer Research

Volumn 7, Issue 7, 2001, Pages 1888-1893

  Figg, W D ^a   Dahut, W ^a   Duray, P ^a   Hamilton, M ^a   Tompkins, A ^a   Steinberg, S M ^a   Jones, E ^a   Premkumar, A ^a   Linehan, W M ^a   Floeter, M K ^a   Chen, C C ^a   Dixon, S ^a   Kohler, D R ^a   Kruger E A ^a   Gubish, E ^a   Pluda, J M ^a   Reed, E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANGIOGENESIS INHIBITOR; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; THALIDOMIDE;

AGED; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FATIGUE; HORMONE DEPENDENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MITOSIS INHIBITION; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL;

AGED; AGED, 80 AND OVER; ANDROGENS; ANGIOGENESIS INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL GROWTH FACTORS; FIBROBLAST GROWTH FACTOR 2; FOLLOW-UP STUDIES; HUMANS; LYMPHOKINES; LYMPHOTOXIN-ALPHA; MALE; MIDDLE AGED; MOOD DISORDERS; NEOVASCULARIZATION, PATHOLOGIC; NEUTROPENIA; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; THALIDOMIDE; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0034783270     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
2. Tumor angiogenesis: Therapeutic implications
3. Diagnostic and therapeutic applications of angiogenesis research
4. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma
5. Thalidomide and congenital abnormalities
6. Thalidomide and congenital abnormalities
7. Thalidomide in treatment of lepra reactions
8. Further observations with thalidomide in lepra reactions
9. Thalidomide for aphthous ulcers in patients infected with the human immunodeficiency virus
10. Thalidomide is an inhibitor of angiogenesis
11. Eligibility and response guidelines for Phase II clinical trials in androgen independent prostate cancer. Recommendations from the Prostate-Specific Antigen Working Group
12. Thalidmide up-regulates prostate-specific antigen (PSA) secretion from LNCaP cells
13. Appendix A, grading of toxicity
14. A 4, 2, and 1 stepping algorithm for quick and accurate estimation of cutaneous sensation threshold
15. Thalidomide: A prodrug that inhibits angiogenesis
16. Inhibition of angioenesis by thalidomide requires metabolic activation, which is species-dependent
17. Increased transcriptional activity of prostate-specific antien in the presence of TNP-470, an angiogenesis inhibitor